Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.58 |
| ▸ | CCND1 | P24385 | 1/20 | 0.58 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035481 | 0.88 | CCNB2 (0.46) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL3445741 | 0.86 | ALDH1A1 (0.49) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL3446508 | 0.86 | ALDH1A1 (0.49) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL29537861 | 0.84 | CCNB2 (0.72) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL433401 | 0.84 | CCNB2 (0.72) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL34465996 | 0.84 | CCNB2 (0.50) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL3446415 | 0.84 | ALDH1A1 (0.54) | L3MBTL1MAPTTDP1SMN1; SMN2ALDH1A1 | |
| Fluoride SCHEMBL27920182 | 0.83 | CCNB2 (0.70) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL21953183 | 0.82 | TDP1 (0.64) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL1050281 | 0.82 | CCNB2 (0.59) | CCNB2CDK1CDK4CCNB1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074859-B | Cyclohexylethyl substituted diaza-and triaza-tricyclics as indoleamine-2, 3-dioxygenase (IDO) antagonists for the treatment of cancer | 默克专利有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-108137497-B | Bicyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-06-15 | — | — | CN | disclosed |
| EP-3313817-B1 | BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2020-09-16 | — | — | EP | disclosed |
| EP-3138831-B1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | HARVARD COLLEGE (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10669244-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-02 | — | — | US | disclosed |
| US-10618909-B2 | Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-04-14 | — | — | US | disclosed |
| US-20190248805-A1 | BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-08-15 | — | — | US | disclosed |
| EP-3189054-B1 | (1-FLUORO-CYCLOHEX-1-YL)-ETHYL SUBSTITUTED DIAZA- AND TRIAZA-TRICYCLIC COMPOUNDS AS INDOLE-AMINE-2,3-DIOXYGENASE (IDO) ANTAGONISTS FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2019-07-24 | — | — | EP | disclosed |
| EP-3189054-B1 | (1-FLUORO-CYCLOHEX-1-YL)-ETHYL SUBSTITUTED DIAZA- AND TRIAZA-TRICYCLIC COMPOUNDS AS INDOLE-AMINE-2,3-DIOXYGENASE (IDO) ANTAGONISTS FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20110009371-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-7807842-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100130451-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2010-05-27 | — | — | US | disclosed |
| EP-0758312-B1 | SUBSTITUTED FUSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | LILLY CO ELI (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0758312-A4 | SUBSTITUTED FUSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | LILLY CO ELI (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0758312-A1 | SUBSTITUTED FUSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ELI LILLY AND COMPANY (US) | 1997-02-19 | — | — | EP | disclosed |
| US-5583221-A | ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS, VIRICIDES, FUNGICIDES | ELI LILLY AND COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| WO-1996005729-A1 | VICINAL-SUBSTITUTED CARBOCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ELI LILLY AND COMPANY (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1995030640-A1 | SUBSTITUTED FUSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
| US-5432198-A | Enzyme inhibitors | SPHINX PHARMACEUTICALS CORPORATION (US) | 1995-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618909-B2 | Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | BAX, CASP3, CASP4 | CCNB2 84/4885CDK1 135/4885CDK4 87/4885 |
| US-20100130451-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | CCNE1, CCNE2, CCNT2 | CCNB2 44/4885CDK1 21/4885CDK4 18/4885 |
| US-20110009371-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | CCNB2 1419/4885CDK1 983/4885CDK4 640/4885 |
| US-20190248805-A1 | BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, CASP3, CASP4 | CCNB2 84/4885CDK1 135/4885CDK4 87/4885 |
| US-10669244-B2 | Synthesis of tetracyclines and analogues thereof | TET1, TET3, MYC | CCNB2 1419/4885CDK1 983/4885CDK4 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.